These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10896900)

  • 21. [New drugs for hepatitis C].
    Färkkilä M
    Duodecim; 2014; 130(18):1813-22. PubMed ID: 25558623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.
    Nakamura J; Toyabe SI; Aoyagi Y; Akazawa K
    J Viral Hepat; 2008 Apr; 15(4):293-9. PubMed ID: 18307591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes and costs of care in hepatitis C: combination therapy scores again.
    Koff RS
    Am J Gastroenterol; 2000 Jun; 95(6):1392-3. PubMed ID: 10894568
    [No Abstract]   [Full Text] [Related]  

  • 24. Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?
    van de Vooren K; Curto A; Garattini L
    Eur J Health Econ; 2015 May; 16(4):341-5. PubMed ID: 25407841
    [No Abstract]   [Full Text] [Related]  

  • 25. Trends in viral hepatitis cost-effectiveness studies.
    Saab S; Choi Y; Rahal H; Li K; Tong M
    Am J Manag Care; 2012 Dec; 18(12):790-8. PubMed ID: 23286609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
    Kim WR; Poterucha JJ; Gross JB
    Hepatology; 2000 Mar; 31(3):807-8. PubMed ID: 10722315
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA approves new combination treatment for hepatitis C. Food and Drug Administration.
    Baker R
    BETA; 1998 Jul; ():10. PubMed ID: 11365553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
    Rubin A; Berenguer M
    Liver Transpl; 2010 Jun; 16(6):697-700. PubMed ID: 20517902
    [No Abstract]   [Full Text] [Related]  

  • 29. A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.
    Tsai PC; Liu TW; Hsieh MH; Yeh ML; Liang PC; Lin YH; Huang CI; Huang CF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2017 Jan; 33(1):44-49. PubMed ID: 28088273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of chronic hepatitis C treatment by interferon-ribavirin combination therapy in Belgium.
    Delwaide J
    Acta Gastroenterol Belg; 2002; 65(4):233-6. PubMed ID: 12619432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.
    Younossi ZM; Singer ME; McHutchison JG; Shermock KM
    Hepatology; 1999 Nov; 30(5):1318-24. PubMed ID: 10534357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of hepatitis C.
    Sjogren MH
    Gastroenterology; 2006 Jul; 131(1):332; author reply 332-3. PubMed ID: 16831622
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of hepatitis C in Rhode Island: opportunities for improvement within and beyond the department of corrections.
    Berzin T; Allen S; Taylor L; Rich J; Feller E
    Med Health R I; 2002 Nov; 85(11):341-4. PubMed ID: 12462866
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations.
    Verma D; Ashkar C; Saab S
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):9-12. PubMed ID: 33073620
    [No Abstract]   [Full Text] [Related]  

  • 35. Economic evaluation of Zepatier for the management of HCV in the Italian scenario.
    Rolli FR; Ruggeri M; Kheiraoui F; Drago C; Basile M; Favaretti C; Cicchetti A
    Eur J Health Econ; 2018 Dec; 19(9):1365-1374. PubMed ID: 29696459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy for hepatitis C infection.
    Clay CM
    N Engl J Med; 1999 Apr; 340(15):1207; author reply 1208-9. PubMed ID: 10206842
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.
    Lin WA; Tarn YH; Tang SL
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1483-93. PubMed ID: 17081165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Financial burden of hepatitis C infection and its treatment].
    Makara M; Hunyady B
    Orv Hetil; 2015 May; 156(21):862-8. PubMed ID: 26038994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
    Hornberger J; Farci P; Prati D; Zeuzem S; Green J; Patel KK
    J Viral Hepat; 2006 Jun; 13(6):377-86. PubMed ID: 16842440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.